MCM
RVMD icon

Manchester Capital Management’s Revolution Medicines RVMD Stock Holding History

Manchester Capital Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.87K Buy
+10
New +$1.46K ﹤0.01% 1053
2024
Q1 		– Sell
-2,782
Closed -$79.8K – 1063
2023
Q4 		$79.8K Buy
+2,782
New +$66.8K 0.01% 376

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Manchester Capital Management's RVMD Position: Q2 2026 in Review

Manchester Capital Management opened a new position in Revolution Medicines (RVMD) in Q2 2026: 10 shares worth $1.87K. The stake represents ﹤0.01% of the portfolio and ranks #1053 among its holdings. This is a return to the name: Manchester Capital Management previously reported a position in RVMD as recently as Q4 2023.

Manchester Capital Management first reported a position in RVMD in Q4 2023 and has held it in 2 quarters since. The position peaked at $79.8K in Q4 2023. 693 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Manchester Capital Management held 10 shares of Revolution Medicines worth $1.87K as of Q2 2026.
  • Revolution Medicines was a new Manchester Capital Management position in Q2 2026.
  • Revolution Medicines made up ﹤0.01% of Manchester Capital Management's portfolio in Q2 2026, its #1053 holding.
  • Manchester Capital Management first reported a position in Revolution Medicines in Q4 2023 and has held it in 2 quarters since.
  • Manchester Capital Management's Revolution Medicines position peaked at $79.8K in Q4 2023.
  • 693 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.